SRR5088924
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.600
- MITOTIC_SPINDLE+0.500
- MYC_TARGETS_V1+0.500
- TGF_BETA_SIGNALING+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- UV_RESPONSE_DN+0.400
- INTERFERON_ALPHA_RESPONSE+0.300
- INTERFERON_GAMMA_RESPONSE+0.300
- ALLOGRAFT_REJECTION+0.200
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.500
- ADIPOGENESIS-0.400
- P53_PATHWAY-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- BILE_ACID_METABOLISM-0.300
- ESTROGEN_RESPONSE_EARLY-0.300
- ESTROGEN_RESPONSE_LATE-0.300
- FATTY_ACID_METABOLISM-0.300
- HEME_METABOLISM-0.300
- MYOGENESIS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518214 | — | D | 0.819 |
| 2 | SRR934755 | — | — | 0.794 |
| 3 | SRR934774 | — | — | 0.787 |
| 4 | TCGA-85-7950-01A-11R-2187-07 | — | cohortSQ1 | 0.778 |
| 5 | TCGA-E2-A1AZ-01A-11R-A12P-07 | — | D | 0.777 |
| 6 | SRR934806 | — | — | 0.768 |
| 7 | TCGA-BA-6873-01A-11R-1873-07 | — | — | 0.767 |
| 8 | SRR934763 | — | — | 0.764 |
| 9 | MDT-AP-3043 | Med | Medulloblastoma | 0.756 |
| 10 | TCGA-91-6848-01A-11R-1949-07 | — | cohortA1 | 0.752 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.600 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.500 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.100 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |